Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added a few more at .076 as we wait patiently for updates.
'When there's blood in the streets, buy property!'
https://www.biorxiv.org/content/10.1101/2020.08.24.265090v1
What is an unrefereed preprint?
Before formal publication in a scholarly journal, scientific and medical articles are traditionally “peer reviewed.” In this process, the journal’s editors take advice from various experts—called “referees”—who have assessed the paper and may identify weaknesses in its assumptions, methods, and conclusions. Typically a journal will only publish an article once the editors are satisfied that the authors have addressed referees’ concerns.
Because this process can be lengthy, authors use the bioRxiv service to make their manuscripts available as “preprints” before completing peer review and consequent certification by a journal. This allows other scientists to see, discuss, and comment on the findings immediately. Readers should therefore be aware that articles on bioRxiv have not been finalized by authors, might contain errors, and report information that has not yet been accepted or endorsed in any way by the scientific or medical community.
and after making this announcement...“We have continued to strengthen our balance sheet, and now have over $100 million in cash and short-term investments as of August 6, 2020, which should provide us with the resources to significantly advance our clinical programs," concluded Mr. Wolf."...management feels a compelling urge to double-dip? Absurd!
Sold all my shares in this bit of strength and I'll patiently wait for a pps well under a buck...
...and then proudly announced he would probably submit an IND in 2021.
Did I miss that? Can you corroborate?
VXRT 8.22 - Question regarding the IND filed on 8/10/20 for their oral COVID-19 Vaccine?
From the FDA website:
An IND application may go into effect:
30 days after FDA receives the application, unless FDA notifies the sponsor that the investigations described in the application are subject to a Clinical Hold; or
on earlier notification by FDA that the clinical investigations in the IND may begin.
https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-application-procedures-overview
My wag is this gets approved before 30 days but I have very limited experience with regard to FDA procedure? I welcome any other wag's out there?
Double down here at 1.35 - just a bit more downspiking and HTBX will be trading at CASH and at which time I'd likely be quadrupling down. A Tier-2-Top-Contender in the race to a Covid-19 vaccine trading at near cash...wow...wow...wow
As of August 4, 2020, there were 148,560,562 shares of Common Stock, $0.0002 par value per share, outstanding.
“We have continued to strengthen our balance sheet, and now have over $100 million in cash and short-term investments as of August 6, 2020, which should provide us with the resources to significantly advance our clinical programs," concluded Mr. Wolf.
That too. and imo TOMZ overwhelms SNFCA in the 'gimmicky-trading' department. I pulled all my TOMZ bids as the possibility grows that they R/S for the uplist spooking the 'gimmicky-traders' followed by a domino-selling-event...not a likelihood, but definitely a growing possibility?
When you compare TOMZ's "10M Revenue/.025 eps" with SNFCA's "118M Revenue/1.10 eps" and compare their almost equal market-caps, it does make one tend to wonder about all things, yes?
SNFCA Cap is actually smaller...
SNFCA 6.42 - added more here - what a brilliant report and it sells off? What? Revenue/EPS thru the roof:
https://old.nasdaq.com/symbol/snfca/revenue-eps
So, in this ludicrous current market, if a company posts an ATROCIOUS report and follows with "things are getting better" it's buy buy buy...but...if a company posts a BRILLIANT report and follows with "might not be sustainable" it's sell sell sell?
Oh my...
SNFCA - Scott M. Quist, President of the Company, said, “We are pleased with the operational performance of our company for the second quarter, and year-to-date. Any time profitability is up approximately 500% quarter over quarter, up essentially 300% YOY, and earning a 13% return on equity for the first half of the year, we should be pleased. For Q2 all of our business segments delivered very solid results.
Well, not all of us ("we")...
SNFCA 6.40 - entered here. Surreal how fundamentals get so little respect in this market...
wade, did I get yours?
"Wait Phase 1 testing or funding." - have been in my HTBX notes for several weeks.
Re-establishing my position here at $1.60. With the global covid-kookout remaining in full swing and no signs of any, other than very vague, common-sense returning in the nearterm, I'm betting that one or both of those catalysts will come about...
The ceo said in an interview...Have they produced a formal document informing shareholders of proprietary ownership? Why? Why not??
Watching no-SEC-disclosure-pinksheet RLFTF trading now above a $1B-Cap on a possible covid therapeutic...does $6M-Cap NBIO have potential room to run?
TOMZ - quote from Dr.Shane:
Most investors appreciate the long-term potential of TOMI and its stock price. Many of our investors understand that concept and as I have stated many times on earnings calls, changing a standard in the world requires a long-term plan.
He is certainly a humble fellow? Lowered my under-a-buck bid even lower...
IGC 1.85 - bought at Friday's close and immediately wrote the Sept.$2.50-calls at .50 cents...almost 30% for 5 weeks. Plus, if a mrinvestpro were to grab-a-holt of IGC, I have an oppurtunity for an additional .65?
Furthermore, as promiscuous as this stock appears, they've kept a clean Balance Sheet and they did cover many bases in this recent PR i.e. FDA-approval(Phase 1), Cannabis, Alzheimers:
announced today that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer’s disease
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14326405&RcvdDate=8/11/2020&CoName=INDIA%20GLOBALIZATION%20CAPITAL,%20INC.&FormType=8-K&View=html
RLFTF is a Swiss Co . You can find disclosures on them such as
I was referring to formal SEC-disclosure. Using my fav covidpennystock, NBIO, as an example and trading right now at an approx. $6M Cap, they show accounting fees for the fiscal year, March 31, 2020 of $13,750.00:
ITEM 14: PRINCIPAL ACCOUNTING FEES AND SERVICE.
Audit fees $13,750
https://www.otcmarkets.com/filing/html?id=14230107&guid=ufG6UpxpMbkrcth
While RLFTF trading right now at a $1B Cap can't afford $13,750 to keep their shareholders informed as per SEC rules of disclosure? hmmmmmmmmm...gamble gamble gamble
RLFTF .54 - there are many reasons why a company would choose non-disclosure...
https://www.otcmarkets.com/stock/RLFTF/disclosure
...and I can't think of ANY good reason, all bad!
BGFV 6.80 - just wrote some Sept.$7.50-calls at .80 cents
TOMZ - and I found this very confusing...
As we saw a 42% growth over our great first quarter, we are thrilled to have reached the $10 million mark for the quarter. We reported on the prior call, due to the strong demand we required a 50% deposit on all machine orders, which brought our revenue to around $8 million for the first seven weeks, all those orders have been shipped.
Therefore they're already at $6M revenue, MINIMUM, for the first half of Q3? Right? The complete refusal to discuss future revenue is puzzling...
An R/S of 5 to 1 would put the pps well above $4 and clean up the share-structure - which imo is sorely needed here.
I read "month".
Also in the plan is an uplist to NASDAQ market in the coming month, trading under the symbol of TOMZ.
https://seekingalpha.com/article/4368591-tomi-environmental-solutions-inc-s-tomz-ceo-dr-halden-shane-on-q2-2020-results-earnings-call?part=single
Anyone care to review uplisting requirements with emphasis on whether an R/S would be required at this current pps?
IGC - I'm bidding 1.55 on the Balance Sheet strength and the sky-high option premiums.
IGC 2.20 (premarket) - they've managed to keep the Balance Sheet clean with no debt and approx. .60-cash. And the sky-high option premiums definitely deserve a further look...but...this one looks over flakey i.e.
Business Wire August 11, 2020...announced today that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study
https://finance.yahoo.com/news/fda-approves-initiation-igc-cannabinoid-210300208.html
What would seem to be super positive news and they wait 12 full days to announce it, hmmmmmm
TOMZ 1.40 - I agree. Another case of allowing the share structure to get out-of-hand in tougher times.
They not only need to uplist, they'll need to R/S prior to the uplist to bring the O/S down...and not a mention of this in filing...maybe in the CC?
BGFV 6.55 - who is Amit Agarwal in this new 13G filing?
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14329560&RcvdDate=8/13/2020&CoName=BIG%205%20SPORTING%20GOODS%20CORP&FormType=SC%2013G&View=html
and I'm sure glad that he didn't stray off into reading hallucinations on yahoo boards?
CLWY 7.00 - joined you here. Wasn't watching, thanks, and these guys should really get uplisted.
ABUS 3.44 - I've been slowly building a position here since it fell back to $5 from the spike to $9's. Basically they appear to likely have of a piece of both MRNA and PFE/BNTX vaccines. Thing is I think it's a stand-alone solid buy in the $4's pps without any covid-19 whatsoever and if they truly do succeed with a patent claim on either or both the two LEADING horses in the race to vaccine - look out above.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157543542
ABUS 3.44 - I've been slowly building a position here since it fell back to $5 from the spike to $9's. Thing is I think it's a stand-alone solid buy in the $4's pps without any covid-19 whatsoever and if they truly do succeed with a patent claim on either or both the two LEADING horses in the race to vaccine - look out above.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157543542
ABUS 3.44 - I've been slowly building a position here since it fell back to $5 from the spike to $9's. Basically they appear to likely have of a piece of both MRNA and PFE/BNTX vaccines. Thing is I think it's a stand-alone solid buy in the $4's pps without any covid-19 whatsoever and if they truly do succeed with a patent claim on either or both the two LEADING horses in the race to vaccine - look out above.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157543542
All these stocks are such yo-yos. I added right before the close at 3.40...
https://www.google.com/search?q=moderna+says+uncertain+about+coronavirus+vaccine+patent&oq=&aqs=chrome.4.69i59l8.36940482j0j15&sourceid=chrome&ie=UTF-8
...because it appears that every major news outlet will be singing this tune in harmony?
Moderna says uncertain about coronavirus vaccine patent exclusivity
REUTERS 10:39 AM ET 8/11/2020
Symbol Last Price Change
MRNA 70.335up -1.675 (-2.33%)
ABUS 3.4838down -0.1762 (-4.81%)
QUOTES AS OF 11:46:42 AM ET 08/11/2020
Aug 11 (Reuters) - Moderna Inc(MRNA) said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing.
The statement by the U.S. drug developer was made in a quarterly filing on Aug. 6 under mandatory disclosures of risks to its business.
Moderna's (MRNA) prior quarterly filings with U.S. regulators did not have the disclosure.
"For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity," the company said. (https://bit.ly/2PISREC)
The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp(ABUS) that poses a potential obstacle to Moderna's(MRNA) efforts to develop next-generation vaccines.
"We cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273," the company said. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
APT 16.40 - also added here at 16.55. I can't forget when it fell to $9's in early June...
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=apt&insttype=&freq=1&show=&time=6
...and I flipped 5K shares twice in one day for right under a buck each time and still kicking myself in the arse for leaving a YUGE stack of chips on the table...
I see a NVAX like move with this stock to $100+ in the coming months.
Back at the White House Big-Pharma meeting in March/2020, INO and NVAX were the two longshot attendees and both fairly equal in fundamental appearance at that time back in March. Today, well I'm not sure I'm interested here anymore at the 15 downgap, lower maybe...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157266808
Agree. Furthermore truly not impressed with today's "Advaccine" update...
In addition, INOVIO is collaborating with Advaccine to advance the development of INO-4800 in China. INOVIO will leverage Advaccine's expertise and has initiated a Phase 1 trial in China in parallel with INOVIO's clinical development efforts in the U.S. and South Korea. In July, regulatory authorities in China approved the clinical testing of INO-4800 by Advaccine in China.
INO was touting "Advaccine" way back in January...
Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing.
https://www.prnewswire.com/news-releases/inovio-collaborating-with-beijing-advaccine-to-advance-ino-4800-vaccine-against-new-coronavirus-in-china-300995916.html
"rapidly" didn't happen...
See Marriott (symbol: MAR) report this morning...got some Gomez Adams action going on there...Sales way WAY down? Negative earnings? But things might get better someday? Buy Buy Buy more and more, Blooker?
VXRT 9.19 - August 10, 2020 - Vaxart Announces IND Filed for COVID-19 Vaccine
https://finance.yahoo.com/news/vaxart-announces-ind-filed-covid-120000578.html
APT 18.24 - found the time to dig into the recent 8-K...
https://finance.yahoo.com/news/correcting-replacing-alpha-pro-tech-190000045.html
...As a result of the ongoing COVID-19 pandemic, demand for our N-95 face masks and other PPE remains strong and shows no indications of slowing as we move into the second half of 2020. Our backlog of orders continues to increase with current delivery commitments into the second quarter of 2021.”
Anyone thinking this global covid19-overblown-freakout is going to pass anytime soon would buy oceanfront property on Great Salt Lake?
...During the second quarter of 2020, the Company brought all available phase 1 N-95 production lines into service and secured raw materials to support the fulfillment of anticipated 2020 orders.
With the phase 1 expansion now completed, Q3 numbers should be much stronger than the stellar Q2 numbers and this is exclusive of the "phase 2 expansion" noted in my previous post...Q4 should provide absolute monster numbers, n'est ce pas?
...Building Supply segment sales for the six months ended June 30, 2020 increased by $1.8 million, or 13.6%, to $15.0 million, compared to $13.2 million for the same period of 2019.
Note the recent positive numbers in most of the homebuilder filings. This longtime established company, APT, is literally firing on all cylinders.
Currently own a healthy long position with more bids below...
...Specifically, our latest pre-clinical studies demonstrated immunogenicity proof-of-concept, validating that the selected vaccine antigen may be appropriate for human testing. Preclinical testing demonstrated expansion of antibody-supporting CD4+, and virus killing CD8+ T-cells in the lungs of the animals, a major site for COVID-19 infection. We believe this platform may play an important role as a standalone vaccine or in combination with other antibody-generating vaccines to provide broad cellular T-cell and humoral protection against COVID-19, particularly for elderly patients and those with underlying health conditions who have an increased risk of complications and death from COVID-19."
https://www.heatbio.com/news-media/news-releases/detail/668/heat-biologics-provides-second-quarter-2020-business-update
I would've guessed they were closer than "may be appropriate"? Will we get a fill of that 1.50 hitch in the chart...possibly also that second hitch at 1.00?
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=htbx&insttype=&freq=1&show=&time=4